Research advances in oxidative stress and mitochondrial permeability transition in liver failure

Wang KeFei; Zhu YueKe; Meng QingHua

doi:10.3969/j.issn.1001-5256.2013.09.021

Issue 9

Sep. 2013

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2013 > 29(9): 711-714

PDF( 688 KB)

Research advances in oxidative stress and mitochondrial permeability transition in liver failure

DOI: 10.3969/j.issn.1001-5256.2013.09.021

Beijing Youan Hospital, Capital Medical University

Research funding:

Received Date: 2013-03-21
Published Date: 2013-09-20

Abstract

Abstract

Major treatment options for liver failure include clinical medical treatment, and prevention of complications) , artificial liver, liver transplantation, and stem cell transplantation. While these means are known to have produced favorable outcomes, some patients died due to acute and severe onset of disease or treatment delays. Oxidative stress has emerged as a research hotspot in recent years and antioxidant treatment has been drawing increasing attention. Outlines research developments in recent years and reviews the association of oxidative stress injury and mitochondrial permeability transition pore ( MPTP) with liver failure, in an effort to shed light on the importance of oxidative stress in the pathogenesis of liver failure and offer a theoretical basis and ideas for antioxidant therapy in the future.
- liver failure,
- mitochondrial membranes,
- oxidative stress

FullText(HTML)

References(48)

References

[1]Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association.Diagnostic and treatment guidelines for liver failure[J].Chin J Hepatol, 2006, 14 (9) :643-646. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J].中华肝脏病杂志, 2006, 14 (9) :643-646.

[2]KUMAR A, DAS K, SHARMA P, et al.Hemodynamic studies in acute-on-chronic liver failure[J].Dig Dis Sci, 2009, 54 (4) :869-878.

[3]KHAN SA, SHAH N, WILLIAMS R, et al.Acute liver failure:a review[J].Clin Liver Dis, 2006, 10 (2) :239-258.

[4]TURRENS JF.Superoxide production by the mitochondrial respiratory chain[J].Biosci Rep, 1997, 17 (1) :3-8.

[5]WANG QL, WANG HY, WANG SR.Assessment of the state of oxidative stress[J].Chin J Pathophysiol, 2005, 21 (10) :2068-2074. (in Chinese) 王秋林, 王浩毅, 王树人, 等.氧化应激状态的评价[J].中国病理生理杂志, 2005, 21 (10) :2068-2074.

[6]WITKO-SARSAT V, FRIEDLANDER M, CAPEIKKEREBLANDIN C, et al.Advanced oxidation protein products as a novel marker of oxidative stress in uremia[J].Kidney Into, 1996, 49 (5) :1304-1313.

[7]LIU H, HAN T, TIAN J, et al.Monitoring oxidative stress in acute-on-chronic liver failure by advanced oxidation protein products[J].Hepatol Res, 2012, 42 (2) :171-180.

[8]CHEN Y, YANG Y, MILLER ML, et al.Hepatocyte-specific Gclc deletion leads to rapid onset of steatosis with mitochondrial injury and liver failure[J].Hepatology, 2007, 45 (5) :1118-1128.

[9]LIU J, TAN H, SUN Y, et al.The preventive effects of heparinsuperoxide dismutase on carbon tetrachloride-induced acute liver failure and hepatic fibrosis in mice[J].Mol Cell Biochem, 2009, 327 (1-2) :219-228.

[10]BOSOI CR, ROSE CF.Oxidative stress:a systemic factor implicated in the pathogenesis of hepatic encephalopathy[J].Metab Brain Dis, 2013, 28 (2) :175-178.

[11]BOVERIS A, CHANCE B.The mitochondrial generation of hydrogen peroxide.General properties and effect of hyperbaric oxygen[J].Biochem J, 1973, 134 (3) :707-716.

[12]ST-PIERRE J, BUCKINGHAM JA, Roebuck SJ, et al.Topology of superoxide production from different sites in the mitochondrial electron transport chain[J].J Biol Chem, 2002, 277 (47) :44784-44790.

[13]STANIEK K, NOHL H.Are mitochondria a permanent source of reactive oxygen species?[J].Biochim Biophys Acta, 2000, 1460 (2-3) :268-275.

[14]LI F, SONVEAUX P, RABBANI ZN, et al.Regulation of HIF-1alpha stability through S-nitrosylation[J].Mol Cell, 2007, 26 (1) :63-74.

[15]NOHL H, GILLE L, STANIEK K.The mystery of reactive oxygen species derived from cell respiration[J].Acta Biochim Pol, 2004, 51 (1) :223-229.

[16]BEDARD K, KRAUSE KH.The NOX family of ROS-generating NADPH oxidases:physiology and path physiology[J].Physiol Rev, 2007, 87 (1) :245-313.

[17]CHANDEL NS, MCCLINTOCK DS, Feliciano CE, et al.Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia:a mechanism of O2sensing[J].J Biol Chem, 2000, 275 (33) :25130-25138.

[18]ALLEN RG, BALIN AK.Oxidative influence on development and differentiation:An overview of a free radical theory of development[J].Free Radic Biol Med, 1989, 6 (6) :631-661.

[19]ANDREYEV AY, KUSHNAREVA YE, STARKOV AA.Mitochondrial metabolism of reactive oxygen species[J].Biochemistry (Mosc) , 2005, 70 (2) :200-214.

[20]RHEE SG.Cell signaling.H2O2, a necessary evil for cell signaling[J].Science, 2006, 312 (5782) :1882-1883.

[21]KINNALLY KW, PEIXOTO PM, RYU SY, et al.Is MPTP the gatekeeper for necrosis, apoptosis, or both?[J].Biochim Biophys Acta, 2011, 1813 (4) :616-622.

[22]HAUSENLOY DJ, ONG SB, YELLON DM.The mitochondrial permeability transition pores as a target for preconditioning and post conditioning[J].Basic Res Cardiol, 2009, 104 (2) :189-202.

[23]SIEMEN D, ZIEMER M.What is the nature of the mitochondrial permeability transition pore and what is it not?[J].IUBMB Life, 2013, 65 (3) :255-262.

[24]HAWORTH RA, HUNTER DR.The Ca2+-induced membrane transition in mitochondria II.Nature of the Ca2+trigger site[J].Arch Biochem Biophys, 1979, 195 (2) :460-467.

[25]BONORA M, BONONI A, De MARCHI E, et al.Role of the c subunit of the FO ATP syntheses in mitochondrial permeability transition[J].Cell Cycle, 2013, 12 (4) :674-683.

[26]REUTENAUER J, DORCHIES OM, PATTHEY-VUADENS O, et al.Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for duchene muscular dystrophy[J].Br J Pharmacol, 2008, 155 (4) :574-584.

[27]RAMACHANDRAN A, LEBOFSKY M, BAINES CP, et al.Cyclophilin D deficiency protects against acetaminophen-induced oxidant stress and liver injury[J].Free Radic Res, 2011, 45 (2) :156-164.

[28]SUSIN SA, DAUGAS E, RAVAGNAN L, et al.Two distinct pathways leading to nuclear apoptosis[J].J Exp Med, 2000, 192 (4) :571-580.

[29] PEIXOTO PM, RYU SY, DEJEAN LM.et al.Is MPTP the gatekeeper for necrosis, apoptosis, or both?[J].Biochim Biophys Acta, 2011, 813 (4) :616-622.

[30]KANG KA, KIM JS, ZHANG R, et al.Induction of hemeoxygenase-1 by plant extract KIOM-79 via Akt pathway and NF-E2 related factor 2 in pancreatic beta-cells[J].J Toxicol Environ Health A, 2008, 71 (20) :1392-1399.

[31]GALLUZZI L, MORSELLI E, KEPP O, et al.Mitochondrial gate ways to cancer[J].Mol Aspects Med, 2010, 31 (1) :1-20.

[32]LIAO MY, ZHOU KJ, et al.Changes of mitochondrial permeability transition during rat liver regeneration[J].Acad J Second Military Med Univ, 2004, 25 (3) :292-294. (in Chinese) 缪明永, 朱克军, 汪振诚, 等.大鼠肝再生时线粒体通透性转换的变化[J].第二军医大学学报, 2004, 25 (3) :292-294.

[33]BERNARDI P.Modulation of the mitochondrial cyclosporin Asensitive permeability transition pores by the proton electrochemical gradient.Evidence that the pore can be opened by membrane depolarization[J].J Biol Chem, 1992, 267 (13) :8834-8839.

[34]BOUGHTON-SMITH NK, EVANS SM, LASZLO F, et al.The induction of nitric oxide synthase and intestinal vascular permeability by endotoxin in the rat[J].Br J Pharmacol, 1993, 110 (3) :1189-1195.

[35]FANG H, CHEN M, DING Y, et al.Imaging superoxide flash and metabolism-coupled mitochondrial permeability transition in living animals[J].Cell Res, 2011, 21 (9) :1295-1304.

[36]MA Q, FANG H, SHANG W, et al.Superoxide flashes:Early mitochondrial signals for oxidative stress-induced apoptosis[J].J Biol Chem, 2011, 286 (31) :27573-27581.

[37]YANG J, LIU X, BHALLA K, et al.Prevention of apoptosis by Bcl-2:release of cytochrome c from mitochondria blocked[J].Science, 1997, 275 (5303) :1129-1132.

[38]CHEN Q, CHAI YC, MAZUMDER S, et al.The late increase in intracellular free radical oxygen species during apoptosis is associated with cytochrome c release, caspase activation, and mitochondrial dysfunction[J].Cell Death Differ, 2003, 10 (3) :323-334.

[39]CHORNA SV, DOSENKO VIE, STRUTYNS'KA NA, et al.Increased expression of voltage-dependent anion channel and adenine nucleotide translocase and the sensitivity of calcium-induced mitochondrial permeability transition opening pore in the old rat heart[J].Fiziol Zh, 2010, 56 (4) :19-25.

[40]SCHRIEWER JM, PEEK CB, BASS J, et al.ROS-mediated PARP activity undermines mitochondrial function after permeability transition pore opening during myocardial ischemia-reperfusion[J].J Am Heart Assoc, 2013, 2 (2) :e000159.

[41]GE ZC, XU HY, HOU WS, et al.Analysis of clinical characteristics and related factors affecting the prognosis of varies liver failure[J].J Clin Hepatol, 2009, 25 (5) :352-354. (in Chinese) 葛宗成, 许慧阳, 候为顺, 等.不同类型肝衰竭临床特点及其转归相关危险因素分析[J].临床肝胆病杂志, 2009, 25 (5) :352-354.

[42]DUAN ZP, CHEN Y.Recent progress and future perspectives of liver failure diagnosis and treatment strategies[J].J Clin Hepatol, 2012, 28 (10) :721-725. (in Chinese) 段钟平, 陈煜.肝衰竭诊疗:进展与展望[J].临床肝胆病杂志, 2012, 28 (10) :721-725.

[43]CHAPPELL JB, CROFTS AR.Calciumion accumulation and volume changes of isolated liver mitochondria.Calciumion-induced swelling.[J].Biochem J, 1965, 95:378-386.

[44]SEN S, DAVIES NA, MOOKERJEE RP, et al.Path physiological effects of albumin dialysis in acute-on-chronic liver failure:a randomized controlled study[J].Liver Transpl, 2004, 10 (9) :1109-1119.

[45]HIGUCHI M, AGGARWAL BB, YEH ET.Activation of CPP32-like protease in tumor necrosis factor-induced apoptosis is dependent on mitochondrial function[J].J Clin Invest, 1997, 99 (7) :1751-1758.

[46]SCHULZE-OSTHOFF K, BAKKER AC, VANHAESEBROECK B, et al.Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions[J].J Biol Chem, 1992, 267 (8) :5317-5323.

[47]VALLANCE P, MONCADA S.Hyperdynamic circulation in cirrhosis:a role for nitric oxide?[J].Lancet, 1991, 337 (8744) :776-778.

[48]HELMY A, JALAN R, NEWBY DE, et al.Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis[J].Hepatology, 2001, 33 (4) :826-831.

Relative Articles

[1]	Jiaxin LIANG, Baolin XU, Yu CHENG, Yong WEI. Role of ferroptosis in hepatic ischemia-reperfusion injury[J]. Journal of Clinical Hepatology, 2024, 40(8): 1693-1698. doi: 10.12449/JCH240830
[2]	Jinrui ZHANG, Hao WU, Yi BAI, Yamin ZHANG. Effect of trimetazidine on a rat model of bile duct ischemia-reperfusion injury and its mechanism[J]. Journal of Clinical Hepatology, 2022, 38(11): 2546-2550. doi: 10.3969/j.issn.1001-5256.2022.11.021
[3]	Zhen LI, Ke WANG, Kaiqiang WANG, Kexian YU. Research advances in targeting autophagy to alleviate hepatic ischemia-reperfusion injury[J]. Journal of Clinical Hepatology, 2022, 38(1): 210-214. doi: 10.3969/j.issn.1001-5256.2022.01.037
[4]	Zhen LI, Yihao ZENG, Ke WANG, Kaiqiang WANG, Kexian YU. Research advances in the prevention and treatment of hepatic ischemia-reperfusion injury with traditional Chinese medicine components[J]. Journal of Clinical Hepatology, 2022, 38(2): 471-476. doi: 10.3969/j.issn.1001-5256.2022.02.044
[5]	Yangyang WANG, Xueying PENG, Jie MENG, Boran AN, Wenjuan HE, Sucai LU, Yan CHEN, Liwen KONG, Chuan NIU, Cong LIU, Wei HUANG, Yingjian HOU. Protective effect of resolvin D1 pretreatment in a rat model of hepatic ischemia-reperfusion injury and its mechanism[J]. Journal of Clinical Hepatology, 2021, 37(6): 1373-1378. doi: 10.3969/j.issn.1001-5256.2021.06.030
[6]	Mi Kai, Huang Rui. Protective effect of urolithin A pretreatment in a rat model of hepatic ischemia-reperfusion injury[J]. Journal of Clinical Hepatology, 2020, 36(8): 1783-1787. doi: 10.3969/j.issn.1001-5256.2020.08.021
[7]	Zhang ShiLong, Peng CiJun, Feng ZanJie, Gao WeiDong, Duan YuLing, Fan GuoXin. Mechanism of action of microRNA in the regulation of hepatic ischemia-reperfusion injury[J]. Journal of Clinical Hepatology, 2019, 35(7): 1629-1631. doi: 10.3969/j.issn.1001-5256.2019.07.045
[8]	Li Yang, Shu DeJun, Peng CiJun, Feng ZanJie, Mei Yong, Xiong Kun. Effect of erythropoietin on the mRNA expression of apoptosis genes bcl-2 and bax in rats with fatty liver disease after hepatic ischemia-reperfusion injury[J]. Journal of Clinical Hepatology, 2019, 35(1): 157-160. doi: 10.3969/j.issn.1001-5256.2019.01.030
[9]	Wang JingYuan, Li ShengWei, Gong JianPing, Jiang DeQuan. Role of silent information regulator 1 in hepatic ischemia-reperfusion injury[J]. Journal of Clinical Hepatology, 2019, 35(6): 1388-1391. doi: 10.3969/j.issn.1001-5256.2019.06.047
[10]	Luo YanQing, Feng ChunLin, Mei Yong, Du Chao, Ceng PengFei, Wang Jun, Wang GuoXing, Zhao Liang, Leng Kai. Protective effect of hepatocyte growth-promoting factor against liver ischemia-reperfusion injury in rats and its mechanism of action[J]. Journal of Clinical Hepatology, 2019, 35(2): 364-367. doi: 10.3969/j.issn.1001-5256.2019.02.024
[11]	Gao WeiDong, Feng ZanJie, Peng CiJun, Li Yang, Wu Bo, Geng Xin. Association between high-mobility group box B1 and hepatic ischemia-reperfusion injury[J]. Journal of Clinical Hepatology, 2019, 35(3): 669-671. doi: 10.3969/j.issn.1001-5256.2019.03.049
[12]	Yang LongCan, Zhang XuYang, Pan NingBo, Yu Xi, Li JiWei, Zhang Ying. Effect of rapamycin on the expression of autophagy-related proteins Unc-51 like autophagy activating kinase 1 and microtubule-associated protein 1 light chain 3 in hepatic ischemia-reperfusion injury and its significance[J]. Journal of Clinical Hepatology, 2019, 35(10): 2261-2265. doi: 10.3969/j.issn.1001-5256.2019.10.026
[13]	Chen BaoHe, Li WenMei. Effect of ulinastatin combined with ischemic preconditioning on hepatic ischemia-reperfusion injury in rats[J]. Journal of Clinical Hepatology, 2018, 34(2): 368-372. doi: 10.3969/j.issn.1001-5256.2018.02.030
[14]	Ren ZhiZhong, Zhang YueWei. Advances in the application of GPC3 in treatment of liver cancer[J]. Journal of Clinical Hepatology, 2017, 33(7): 1369-1372. doi: 10.3969/j.issn.1001-5256.2017.07.037
[15]	Xu Feng, Liu XiaoLin, Wang Chao, Dai ChaoLiu. Protective effect of prostaglandin E1 pretreatment against liver ischemia-reperfusion injury in rats with cholestasis[J]. Journal of Clinical Hepatology, 2017, 33(5): 899-904. doi: 10.3969/j.issn.1001-5256.2017.05.022
[16]	Wang QingQing, Zhao Xin, Chen YuChao, Dou Jian. Research advances in mechanisms and intervention of hepatic ischemia-reperfusion injury[J]. Journal of Clinical Hepatology, 2016, 32(6): 1225-1229. doi: 10.3969/j.issn.1001-5256.2016.06.049
[17]	Chen XuXiao, Chen YongJun. PI3K / Akt / mTOR signaling pathway and malignant hepatobiliary tumors[J]. Journal of Clinical Hepatology, 2015, 31(6): 989-991. doi: 10.3969/j.issn.1001-5256.2015.06.040
[18]	Wu ZhangHui, Shen Min, Li Long, Wei Jia. Association between PI3K/Akt/mTOR/p70S6K signaling pathway and hepatic fibrosis[J]. Journal of Clinical Hepatology, 2015, 31(11): 1928-1932. doi: 10.3969/j.issn.1001-5256.2015.11.043
[19]	Wu Gang, Zheng Jie, Hu GuoXin, Peng YanZhong. Role of liver nonparenchymal cells in hepatic ischemia-reperfusion injury[J]. Journal of Clinical Hepatology, 2014, 30(12): 1366-1369. doi: 10.3969/j.issn.1001-5256.2014.12.033
[20]	Gao Jun, Chen Gong, Lu: Long. Protective role and immunoregulatory effect of CXCR3 in hepatic ischemia- reperfusion injury[J]. Journal of Clinical Hepatology, 2014, 30(8): 790-794. doi: 10.3969/j.issn.1001-5256.2014.08.023

Supplements(0)

Cited By

Cited by

Periodical cited type(30)

1.	汪淑佳，俞黎. 多学科团队诊疗模式下的PDCA循环管理在梗阻性黄疸患者围术期护理中的应用效果分析. 中国社区医师. 2025(02): 96-98 .
2.	易衡，何芬，王曦，冯谦，唐杰，卿小琼，孙菲菲，陈重. 超声引导下PTCD治疗晚期MOJ疗效及预后因素分析. 武汉大学学报(医学版). 2024(07): 814-819 .
3.	李鸿. 老年晚期恶性梗阻性黄疸患者实时超声弹性成像定量分析对PTCD预后的预测价值. 昆明医科大学学报. 2023(01): 122-127 .
4.	李鸿. 老年晚期恶性梗阻性黄疸患者实时超声弹性成像定量分析对PTCD预后的评估价值. 昆明医科大学学报. 2023(02): 150-155 .
5.	梁亚丽，李馨，夏俊杰. 胰腺癌梗阻性黄疸患者经皮穿刺胆管引流术后发生胰腺炎的危险因素分析. 实用癌症杂志. 2023(08): 1321-1324 .
6.	杨立新，刘茜，周晶晶，唐亚丹，傅鹏，戴峰，白淑芬. 不同方法PTCD应用于梗阻性黄疸治疗中的体会. 现代医用影像学. 2023(12): 2229-2231+2235 .
7.	华建军. 超声引导下经皮肝穿刺胆管引流术治疗对阻塞性黄疸病人胆红素水平与肝功能的影响研究. 贵州医药. 2022(02): 226-227 .
8.	黄道琼，沈小叶，刘骏，刘月娥，陈瑜. 回授法在经皮肝穿刺胆管引流术后的应用. 介入放射学杂志. 2022(03): 294-297 .
9.	彭赵宏，张德志，施万印，赵本胜，熊壮，汪名权，宋文，陶龙香，刘斌，张帅，程翔. ~(125)I粒子支架治疗恶性梗阻性黄疸支架通畅时间的影响因素分析. 安徽医科大学学报. 2022(04): 645-649 .
10.	王玮，陈熙，罗丹，李启祥，尹合坤. 不同姑息性引流术对低位恶性梗阻性黄疸的近远期疗效及安全性分析. 当代医学. 2022(19): 39-42 .
11.	买买提·瓦司力，高旭升，司俊杰，徐峰. 经皮肝穿引流和支架植入在恶性梗阻性黄疸患者治疗的疗效评价. 新疆医学. 2022(07): 770-772+809 .
12.	王颖. 彩超引导经皮穿刺肝胆管引流术治疗梗阻性黄疸的临床研究. 中国医疗器械信息. 2022(15): 123-125 .
13.	宋飞，向盈盈，车佳音，李红阳，徐文勇，魏凌潇，黄明. 胆道~(125)I粒子支架与金属裸支架治疗Bismuth Corlette Ⅲ型胆管癌合并梗阻性黄疸的临床对比. 昆明医科大学学报. 2022(11): 85-89 .
14.	冉庆. ERCP联合PTCD胆总管支架置入胆管引流治疗恶性梗阻性黄疸的临床价值. 医学食疗与健康. 2021(04): 86-87 .
15.	王锦程，余佩和，苏松，李波. 经内镜鼻胆管引流术与经内镜胆道支架置入术在低位恶性梗阻性黄疸术前胆道引流效果比较的Meta分析. 临床肝胆病杂志. 2021(04): 863-867 . 本站查看
16.	马博，周军，周京涛，李建刚，王俊. 胆道支架植入治疗恶性梗阻性黄疸术后并发症的发生因素分析. 现代生物医学进展. 2021(07): 1283-1286 .
17.	张建松，侯森，崔虎啸. 超声引导下经皮肝穿刺胆道引流联合胆管复合支架置入术治疗晚期肝外胆管癌的效果. 癌症进展. 2021(09): 931-934 .
18.	张华安，周晓芳，蒋易君，张淏嘉. NRS-2002联合炎症反应标志物预测恶性梗阻性黄疸患者预后的Nomogram模型构建. 山东医药. 2021(16): 35-40 .
19.	石书伟，王劲. 经皮肝穿刺胆道引流联合金属支架植入术对恶性梗阻性黄疸的影响. 黑龙江医学. 2021(15): 1608-1609 .
20.	宋英茜，陶冶. 梗阻性黄疸经皮肝穿刺胆道引流术后胆道感染的病原菌特点及其危险因素分析. 中国实用乡村医生杂志. 2021(02): 33-36 .
21.	张志强，韩涛，崔钢，王奕，蔡恒烈，廖骞. 右肝管入路单通道横跨左右肝管引流治疗汇管区恶性梗阻性黄疸的临床研究. 中国普通外科杂志. 2021(12): 1503-1508 .
22.	傅建英. 内镜介入治疗急性梗阻性黄疸的疗效及对患者炎症因子的影响. 中外医疗. 2021(33): 57-60 .
23.	李蔚，王锡斌，崔卫东，杨青，刘会苗，杨金雨，王锡斌. 超声引导下经皮经肝胆管穿刺引流术治疗急性梗阻性化脓性胆管炎患者疗效分析. 实用肝脏病杂志. 2020(03): 447-450 .
24.	李磊. 胆道支架联合经皮肝穿刺胆管引流术对晚期恶性梗阻性黄疸的临床应用价值. 名医. 2020(08): 85-86 .
25.	张蓓，答秀维，张乐. 经皮肝穿刺胆道外引流治疗恶性梗阻性黄疸疗效及对患者细胞免疫功能、血清直接胆红素、超敏C反应蛋白水平的影响. 陕西医学杂志. 2020(10): 1249-1252 .
26.	朱超，刘会春，胡小四，庞青，陈邦邦，李传涛. 胆道双支架联合~(125)I粒子腔内照射治疗恶性肝门部胆道梗阻的疗效分析. 介入放射学杂志. 2020(11): 1100-1104 .
27.	姜磊，都晓英，孙医学，张大坤，周凯，徐建中，陈芳芳. PTBS术治疗恶性梗阻性黄疸的临床价值及预后因素分析. 蚌埠医学院学报. 2019(09): 1202-1205+1209 .
28.	江新华. 64层螺旋CT3D成像与MRCP成像技术对胆道梗阻性疾病的诊断价值. 江西医药. 2019(11): 1336-1340 .
29.	吴子鑫，吴申伟. 经皮肝穿刺胆道支架植入治疗对恶性梗阻性黄疸患者肝功能指标、炎症指标的影响. 齐齐哈尔医学院学报. 2019(24): 3098-3099 .
30.	武飞. 经皮肝穿刺胆管引流术与Roux-en-Y胆肠吻合术治疗恶性梗阻性黄疸患者的对比研究. 中国药物与临床. 2019(23): 4098-4100 .

Other cited types(4)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2776) PDF downloads(618)

Research advances in oxidative stress and mitochondrial permeability transition in liver failure

DOI: 10.3969/j.issn.1001-5256.2013.09.021